Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Skye Biosciences, Inc. (“Skye” or the “Company”) (Nasdaq: SKYE) and reminds investors of the January 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
On October 6, 2025, Skye issued a press release “announcing the topline data from its 26-week Phase 2a CBeyond™ proof-of-concept study of nimacimab, its peripherally-restricted CB1 inhibitor antibody.” The press release disclosed that the “the nimacimab monotherapy arm did not achieve the primary endpoint of weight loss compared to placebo” and that “preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy.”
On this news, Skye’s stock price fell $2.85 per share, or 60%, to close at $1.90 per share on October 6, 2025.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Skye’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Skye Bioscience class action, go to www.faruqilaw.com/SKYE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f7c4b666-65e2-42bc-b437-227a7c8e271d
